#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    PIK3CA-activated mutation Thalassaemia Leukaemia Mucopolysaccharidosis I Hodgkin's disease Skin angiosarcoma Ovarian cancer stage III Plasma cell myeloma recurrent Glycogen storage disease type V Hypochondroplasia Stevens-Johnson syndrome Adenomatous polyposis coli Bronchiolitis Osteogenesis imperfecta Vulval cancer recurrent More trials…

    Learn about Rare Diseases

    Systemic sclerosis pulmonary Pelizaeus-Merzbacher disease – Life with Disease Prolymphocytic leukaemia – Treatment Factor VIII deficiency – Life with Disease Undifferentiated sarcoma – Basic Information Biotinidase deficiency Factor IX deficiency – Treatment Pemphigoid – Diagnostics Ornithine transcarbamoylase deficiency – Diagnostics Methylmalonic acidaemia – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Zoledronic Acid Monohydrate Buparlisib Paclitaxel Obaluronate Lufepirsen Betaine Citrate Mosunetuzumab Garetosmab Pilocarpine Hydrochloride Heterodimeric Interleukin-15 Cefepime Cenegermin Methoxyflurane OBI-821 ALXN2420 Triamcinolone EGANELISIB Methyl Aminolevulinate Antipsychotics Diclofenac Diethylamine Troriluzole More therapies…

    Learn about Your Condition

    Autoimmune uveitis Epidermolysis bullosa Renal injury Hepatic cancer Encephalopathy neonatal Pseudomonas infection Aplastic anaemia Coeliac disease Procedural pain Laryngeal cancer stage III Postoperative delirium Rectal adenocarcinoma Notalgia paraesthetica Hypoxia Incisional hernia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • A study to test the safety and effectiveness of BAY 3713372 alone and with drug combination in patients with MTAP-deleted solid tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Belgium Czechia Denmark Italy The Netherlands Spain +1

  • A Study Testing AOC 1020 to Improve Movement in Adults with Facioscapulohumeral Muscular Dystrophy

    Recruiting

    3 1
    Investigated Diseases:
    • Facioscapulohumeral muscular dystrophy
    Investigated Drugs:
    • Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dux4 Mrna Via A Non-Cleavable Linker
    Denmark France Germany Italy The Netherlands Spain

  • Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

    Recruiting

    3 1
    Investigated Drugs:
    • Vorasidenib
    Austria Belgium Czechia France Germany Italy +2

  • A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Erdafitinib
    • Gemcitabine Hydrochloride
    • Mitomycin
    Belgium France Germany Greece Italy The Netherlands +1

  • A Study Testing Anti-CD19 CAR T-Cell Therapy in Patients with Systemic Sclerosis Who Did Not Respond to Immunosuppressive Drugs

    Recruiting

    2 1 1
    Investigated Diseases:
    • Systemic scleroderma
    Investigated Drugs:
    • Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
    France

  • A Study of Repinatrabit Compared to Placebo for Treatment of Patients with Phenylketonuria

    Recruiting

    3 1
    Czechia France Germany Italy The Netherlands Poland +1
Previous Page
1 … 106 107 108 109 110 … 1,646
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!